These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2193994)

  • 21. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.
    Frampton JE; Perry CM
    Drugs Aging; 2006; 23(12):977-95. PubMed ID: 17154662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
    Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
    Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of D-timolol and L-timolol on ocular blood flow and intraocular pressure.
    Chiou GC; Zhao F; Shen ZF; Li BH
    J Ocul Pharmacol; 1990; 6(1):23-30. PubMed ID: 2362158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.
    Sakanaka K; Kawazu K; Tomonari M; Kitahara T; Nakashima M; Nishida K; Nakamura J; Sasaki H; Higuchi S
    Biol Pharm Bull; 2008 Aug; 31(8):1590-5. PubMed ID: 18670094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
    Heijl A; Strahlman E; Sverrisson T; Brinchman-Hansen O; Puustjärvi T; Tipping R
    Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Histamine H₃ Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma.
    Lanzi C; Lucarini L; Durante M; Sgambellone S; Pini A; Catarinicchia S; Łażewska D; Kieć-Kononowicz K; Stark H; Masini E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
    Lorenz K; Pfeiffer N
    Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension.
    Fuchsjäger-Mayrl G; Wally B; Rainer G; Buehl W; Aggermann T; Kolodjaschna J; Weigert G; Polska E; Eichler HG; Vass C; Schmetterer L
    Br J Ophthalmol; 2005 Oct; 89(10):1293-7. PubMed ID: 16170119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension.
    Walters TR; Maloney S; Slater D; Liss C; Wilson H; Hartenbaum D
    Clin Ther; 1998; 20(6):1170-8. PubMed ID: 9916610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension.
    Dixon ER; Landry T; Venkataraman S; Gustafson N; Salem C; Bradfield Y; Aljasim LA; Feldman R
    J AAPOS; 2017 Oct; 21(5):370-374.e1. PubMed ID: 28887006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Travoprost--a new prostaglandin analogue for the treatment of glaucoma.
    Whitson JT
    Expert Opin Pharmacother; 2002 Jul; 3(7):965-77. PubMed ID: 12083996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oculohypotensive effects of foeniculum vulgare in experimental models of glaucoma.
    Agarwal R; Gupta SK; Agrawal SS; Srivastava S; Saxena R
    Indian J Physiol Pharmacol; 2008; 52(1):77-83. PubMed ID: 18831355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
    Hartenbaum D
    Clin Ther; 1996; 18(3):460-5. PubMed ID: 8829021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans.
    Gandolfi SA; Vecchi M
    Invest Ophthalmol Vis Sci; 1996 Mar; 37(4):684-8. PubMed ID: 8595970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.